Structure Therapeutics (NASDAQ:GPCR) Trading Down 4.2% - What's Next?

Key Points

• Structure Therapeutics shares fell 4.2% to $16.85, with a significant decline in trading volume, indicating decreased investor interest.
• Analysts have a consensus rating of "Buy" for Structure Therapeutics, with varied price targets averaging $76.17, reflecting positive market sentiment despite recent stock performance.
• The company reported a quarterly loss of ($0.27) EPS, missing analysts' expectations, which may impact future investor confidence.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report)'s share price dropped 4.2% on Monday . The company traded as low as $16.91 and last traded at $16.85. Approximately 344,175 shares changed hands during trading, a decline of 60% from the average daily volume of 855,725 shares. The stock had previously closed at $17.59.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on GPCR. Citigroup began coverage on Structure Therapeutics in a research report on Friday, May 2nd. They set a "buy" rating and a $60.00 target price on the stock. HC Wainwright reduced their price target on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Monday, May 12th. JMP Securities restated a "market outperform" rating and set a $89.00 price objective on shares of Structure Therapeutics in a research report on Monday, June 23rd. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, June 23rd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $76.17.

Structure Therapeutics Price Performance

The stock's 50-day moving average price is $20.43 and its 200 day moving average price is $22.15. The firm has a market cap of $962.17 million, a P/E ratio of -19.29 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new stake in shares of Structure Therapeutics in the fourth quarter worth about $34,000. Virtus ETF Advisers LLC grew its holdings in shares of Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after purchasing an additional 455 shares during the last quarter. Assetmark Inc. boosted its holdings in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company's stock valued at $60,000 after acquiring an additional 820 shares in the last quarter. National Bank of Canada FI boosted its holdings in shares of Structure Therapeutics by 1,448.2% during the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after buying an additional 2,766 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Structure Therapeutics by 673.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after buying an additional 3,549 shares in the last quarter. Institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.